BKV Corp Form 8-K Summary
Business Context and Reporting Period
BKV Corporation (BKV), an emerging growth company incorporated in Delaware, filed this Current Report on Form 8-K dated January 22, 2026. The filing reports the submission of matters to a vote of security holders via written consent.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on corporate governance and equity plan amendments.
Material Changes and Corporate Actions
- Equity Plan Amendment: On January 22, 2026, Banpu North America Corporation (the "Consenting Majority Stockholder"), holding approximately 66% of outstanding shares, consented in writing to amend and restate the BKV Corporation 2024 Equity and Incentive Compensation Plan (the "A&R 2024 Plan").
- Share Increase: The amendment increases the number of shares of Common Stock available for grant and issuance under the plan by 2,500,000 shares.
- Plan Scope: The plan continues to provide for non-qualified stock options, appreciation rights, restricted stock awards, restricted stock units, cash incentive awards, performance shares, and performance units for eligible directors, officers, and employees.
- Shareholder Approval: The Board approved the plan on December 17, 2025, subject to the written consent received. As of January 20, 2026, there were 96,972,345 shares of Common Stock issued and outstanding. The Consenting Majority Stockholder held 63,877,614 shares.
Outlook, Risks, and Effective Date
The Company will file an Information Statement on Schedule 14C with the SEC and distribute it to stockholders of record as of January 20, 2026. The A&R 2024 Plan will become effective no earlier than 20 days from the date the Information Statement is first sent or given to stockholders. No specific risks, contingencies, or unusual items were disclosed in this filing.
Investor Verification Checklist
- Verify the receipt and content of the upcoming Schedule 14C Information Statement.
- Confirm the exact effective date of the A&R 2024 Plan once the 20-day waiting period concludes.
- Review the total number of shares authorized under the amended plan to assess potential future dilution.
- Monitor subsequent filings for any changes in the Consenting Majority Stockholder's position or voting power.